<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    17110817
   </pmid>
   <datecreated>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     19
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2007
    </year>
    <month>
     02
    </month>
    <day>
     07
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2008
    </year>
    <month>
     09
    </month>
    <day>
     11
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0271-0749
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       26
      </volume>
      <issue>
       6
      </issue>
      <pubdate>
       <year>
        2006
       </year>
       <month>
        Dec
       </month>
      </pubdate>
     </journalissue>
     <title>
      Journal of clinical psychopharmacology
     </title>
     <isoabbreviation>
      J Clin Psychopharmacol
     </isoabbreviation>
    </journal>
    <articletitle>
     Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
    </articletitle>
    <pagination>
     <medlinepgn>
      600-9
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      This study evaluated the efficacy and tolerability of quetiapine monotherapy for depressive episodes in patients with bipolar I or II disorder (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) who were randomized to 8 weeks of double-blind treatment with quetiapine (300 or 600 mg/d; once daily, evening dosing) or placebo. Patients were assessed weekly using the Montgomery-Asberg Depression Rating Scale (MADRS) and Hamilton Depression Rating Scale (HAM-D). The primary end point was change in MADRS total score from baseline to Week 8 (analysis of covariance/last-observation-carried-forward analysis). Of 509 patients randomized, 59% completed the study. Improvements from baseline in mean MADRS total scores were significantly greater with quetiapine 300 and 600 mg/d than with placebo from first evaluation (Week 1) through Week 8 (both P &lt;or= 0.001 vs. placebo). Therapeutic effect sizes at Week 8 were 0.61 and 0.54 for quetiapine 300 and 600 mg/d, respectively. Improvements in mean HAM-D scores were also significantly greater with both quetiapine doses than with placebo (P &lt; 0.001) as early as Week 1 and throughout the study. The MADRS response and remission rates were also significantly greater in both quetiapine dose groups compared with placebo. Improvements in primary and secondary outcomes were observed with both 300 and 600 mg/d quetiapine without major differences between the doses. Common adverse events included dry mouth, sedation, somnolence, dizziness, and constipation. The incidence of treatment-emergent mania or hypomania was lower with quetiapine treatment than placebo. This study demonstrates that quetiapine monotherapy is an effective and well-tolerated treatment for depressive episodes in bipolar disorder, confirming the results observed from a previous study (BipOLar DEpRession [BOLDER] I).
     </abstracttext>
    </abstract>
    <affiliation>
     Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213-2593, USA. thaseme@upmc.edu
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Thase
      </lastname>
      <forename>
       Michael E
      </forename>
      <initials>
       ME
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Macfadden
      </lastname>
      <forename>
       Wayne
      </forename>
      <initials>
       W
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Weisler
      </lastname>
      <forename>
       Richard H
      </forename>
      <initials>
       RH
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Chang
      </lastname>
      <forename>
       William
      </forename>
      <initials>
       W
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Paulsson
      </lastname>
      <forename>
       Bj√∂rn
      </forename>
      <initials>
       B
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Khan
      </lastname>
      <forename>
       Arifulla
      </forename>
      <initials>
       A
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Calabrese
      </lastname>
      <forename>
       Joseph R
      </forename>
      <initials>
       JR
      </initials>
     </author>
     <author validyn="Y">
      <collectivename>
       BOLDER II Study Group
      </collectivename>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     J Clin Psychopharmacol
    </medlineta>
    <nlmuniqueid>
     8109496
    </nlmuniqueid>
    <issnlinking>
     0271-0749
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antipsychotic Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Dibenzothiazepines
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      quetiapine
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Evid Based Ment Health. 2007 Aug;10(3):82
     </refsource>
     <pmid version="1">
      17652564
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      J Clin Psychopharmacol. 2008 Jun;28(3):367-8; author reply 368
     </refsource>
     <pmid version="1">
      18480707
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      J Clin Psychopharmacol. 2008 Jun;28(3):367; author reply 368
     </refsource>
     <pmid version="1">
      18480708
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="ErratumIn">
     <refsource>
      J Clin Psychopharmacol. 2007 Feb;27(1):51
     </refsource>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Analysis of Variance
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antipsychotic Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anxiety Disorders
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      psychology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bipolar Disorder
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      physiopathology
     </qualifiername>
     <qualifiername majortopicyn="N">
      psychology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diagnostic and Statistical Manual of Mental Disorders
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dibenzothiazepines
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Least-Squares Analysis
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Psychiatric Status Rating Scales
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Quality of Life
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Severity of Illness Index
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Time Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N" type="Geographic">
      United States
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2006
     </year>
     <month>
      11
     </month>
     <day>
      18
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2007
     </year>
     <month>
      2
     </month>
     <day>
      8
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2006
     </year>
     <month>
      11
     </month>
     <day>
      18
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="doi">
     10.1097/01.jcp.0000248603.76231.b7
    </articleid>
    <articleid idtype="pii">
     00004714-200612000-00009
    </articleid>
    <articleid idtype="pubmed">
     17110817
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

